'Trials For Nasal Covid Vaccine Slated For November'
"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1548839_1_20200910182024.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1548839-20200910.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1548839-20200910.htm', 'DCS.dcsqry', '' ); } } }); }); });
2020-09-10 HKT 11:42
Hong Kong University microbiologist Professor Yuen Kwok-yung said they hope to start clinical trials for a new nasal spray vaccine for Covid-19 in November.
Yuen, who is the chair of infectious diseases at the university's department of microbiology, made the comments after HKU announced that mainland authorities had given the go ahead for clinical trials for the nasal spray – which it has been developing with some mainland institutions.
Speaking on a Commercial Radio programme, Yuen said that the university has received funding of about HK$20 million from the authorities, and they hope to recruit about 100 healthy people in Hong Kong for the trials.
He said that vaccine development requires three phases of clinical trials, and after the launch of phase one this year, it will take about one more year at the earliest before the vaccine can be used.
HKU's State Key Laboratory of Emerging Infectious Diseases has been working on the vaccine with Xiamen University and Beijing Wantai Biological Pharmacy.
Yuen said that since Hong Kong does not have its own facilities for developing vaccines, it needs to cooperate with the mainland.
HKU said their vaccine is so far the only nasal spray vaccine against the coronavirus to be approved by the National Medical Products Administration for clinical trials.
HKMA Warns Of Fake Stablecoins As Licensed Issuers Have Yet To Launch Tokens
The Hong Kong Monetary Authority (HKMA) has warned the public about fake stablecoins in Hong Kong, specifically flaggin... Read more
Tazapay Secures Money Service Operator License In Hong Kong
Singapore-based cross-border payments company Tazapay has secured a Money Service Operator (MSO) license in Hong Kong. ... Read more
Livi Bank Posts First Full-Year Profit In 2025 As Loans Rise 49%
Hong Kong digital bank livi bank reported a full-year profit of HK$21 million for 2025. For the year, total operating i... Read more
FWD Group Reports US$720M In New Business Sales As Expansion Continues
FWD Group reported a 4% year-on-year increase in new business sales to US$720 million for the first quarter of 2026, dr... Read more
WeLab Bank 2025 Revenue Hits HK$942M After Securing First-Half Profitability
WeLab Bank achieved profitability in the first half of 2025 and reported a 35% year-on-year revenue increase to HK$942 ... Read more
Ripple And Kbank Roll Out Institutional Digital Asset Wallet In South Korea
Ripple has partnered with Kbank to deploy an institutional digital asset wallet in Korea, equipping the internet bank w... Read more
